
Novartis' lipid-lowering drug Leqvio clears reimbursement hurdle on 1st attempt
Novartis' twice-yearly lipid-lowering subcutaneous injection Leqvio (inclisiran) has passed the Pharmaceutical Reimbursement Evaluation Committee (PREC) on its first challenge. However, it was decided to rediscuss Ipsen's Bylvay (odevixibat), which …